drugset / Trial / NCT06727357
Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP
RandomizedParallel-groupSingle-blindTreatment
Summary
The present trial clinical proposes to randomize patients with cancer metastatic disease of the breast progressing on standard therapy to receive a treatment selected from 4 "targeted" drugs (a MEK kinase inhibitor, an mTOR kinase inhibitor, an of the enzyme involved in DNA repair PARP and an androgen receptor inhibitor) on the basis of possible presence of mutations in a panel of 61 genes analyzed on metastatic tissue from biopsy, or receive standard chemotherapy.
Timeline
- Start
- 2019-09-26
- Primary completion
- 2025-03
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | — | — |
| Subject | Olaparib | Small molecule | — | — |
| Subject | Selumetinib | Small molecule | — | — |
| Subject | Vistusertib | Small molecule | — | — |